NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

MiNK Therapeutics logo
$8.02 -0.59 (-6.85%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$7.81 -0.21 (-2.59%)
As of 11/20/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MiNK Therapeutics Stock (NASDAQ:INKT)

Advanced

Key Stats

Today's Range
$7.76
▼
$8.60
50-Day Range
$8.02
▼
$12.73
52-Week Range
$7.76
▼
$16.93
Volume
19,031 shs
Average Volume
14,769 shs
Market Capitalization
$41.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00
Consensus Rating
Hold

Company Overview

MiNK Therapeutics is a clinical-stage biotechnology company developing cell therapies for cancer and immune-mediated diseases. Its research focuses on invariant natural killer T (iNKT) cells, which can interact with both innate and adaptive immune responses.

The company’s lead candidate, agenT-797, is an allogeneic, off-the-shelf iNKT cell therapy being studied for solid tumors. MiNK’s approach is intended to make donor-derived cell treatments available without requiring cells to be manufactured individually for each patient.

MiNK’s work centers on advancing its iNKT cell platform and clinical-stage therapies. Its development programs remain investigational; the company has not established a broad commercial product portfolio.

AI Generated. May Contain Errors.

MiNK Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

INKT MarketRank™: 
1.996075133165 of 5 stars

MiNK Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 624th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    MiNK Therapeutics has a consensus price target of $44.00, representing about 448.6% upside from its current price of $8.02.

  • Amount of Analyst Coverage

    MiNK Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about MiNK Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MiNK Therapeutics are expected to grow in the coming year, from ($2.31) to ($1.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MiNK Therapeutics is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MiNK Therapeutics is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.36% of the float of MiNK Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MiNK Therapeutics has a short interest ratio ("days to cover") of 4.29.
  • Change versus previous month

    Short interest in MiNK Therapeutics has recently increased by 15.31%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MiNK Therapeutics does not currently pay a dividend.

  • Dividend Growth

    MiNK Therapeutics does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MiNK Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,265.00 in company stock.

  • Percentage Held by Insiders

    20.40% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    2.87% of the stock of MiNK Therapeutics is held by institutions.

  • Read more about MiNK Therapeutics' insider trading history.
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INKT Stock News Headlines

FY2026 EPS Forecast for MiNK Therapeutics Raised by Analyst
What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

INKT Stock Analysis - Frequently Asked Questions

MiNK Therapeutics' stock was trading at $11.15 at the start of the year. Since then, INKT shares have decreased by 28.1% and is now trading at $8.02.

MiNK Therapeutics, Inc. (NASDAQ:INKT) posted its earnings results on Wednesday, November, 11th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.16. The company earned $200 thousand during the quarter, compared to analysts' expectations of $75 thousand.
Read the conference call transcript
.

MiNK Therapeutics shares reverse split before market open on Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

MiNK Therapeutics (INKT) raised $43 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), NVIDIA (NVDA), SoFi Technologies (SOFI), Warner Bros. Discovery (WBD), BigBear.ai (BBAI), Walt Disney (DIS) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
11/11/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INKT
CIK
1840229
Fax
N/A
Employees
15
Year Founded
2017

Price Target and Rating

High Price Target
$50.00
Low Price Target
$38.00
Potential Upside/Downside
+448.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.49 million
Net Margins
N/A
Pretax Margin
-5,511.50%
Return on Equity
N/A
Return on Assets
-103.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.97
Quick Ratio
0.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.17) per share
Price / Book
-2.53

Miscellaneous

Outstanding Shares
5,130,000
Free Float
4,087,000
Market Cap
$41.14 million
Optionable
No Data
Beta
0.49

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:INKT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners